According to 7 Hills Pharma, a clinical stage immunotherapy company focused on the development of drugs for treatment and prevention of cancer and infectious diseases, preclinical studies reveal 7HP349, an oral integrin activator that promotes cell adhesion, significantly increases IgG binding antibodies with a vaccine targeting SARS-CoV-2 (COV2), the virus that causes COVID-19.   The data also suggest 7HP349 can be used as an immunostimulant for any COVID-19 vaccine and has the potential not on...